12/3/2023 0 Comments Kite pharma yahoo finance![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. While Gilead and Actelion are Zacks Rank #1 (Strong Buy) stocks, Juno holds a Zacks Rank #2 (Buy). Some better-ranked stocks in the health care sector are Gilead Sciences Inc. Kite Pharma currently carries a Zacks Rank #3 (Hold). With no approved product in Kite Pharma’s portfolio at the moment, we expect investor focus to remain on pipeline updates from the company. We note that CAR T cell therapies have been attracting a lot of attention lately with pharmaceutical and biotech majors eyeing an entry in this therapeutic area.Īpart from Kite Pharma, Juno Therapeutics JUNO is also working on developing therapies utilizing CAR T cell technology. ![]() DLBCL, PMBCL and TFL are all aggressive forms of NHL. We are encouraged by Kite Pharma’s progress with KTE-C19. We note that KTE-C19 enjoys orphan drug status for DLBCL both in the U.S. The likely reason for the leap is the just-announced 12 billion Kite Pharma/ Gilead deal. ![]() and potentially launch the candidate in 2017.Īpart from the phase I/II study, the company expects to begin three additional studies on KTE-C19 before 2015 end. Shares in IMMU, a preclinical biopharma, rose from 10.50 to 11.84 on August 28. Positive results would allow the company to file for approval in the U.S. Pivotal data from the first study on KTE-C19 should be out in 2016. Following the completion of the phase I part of the study, Kite Pharma intends to advance KTE-C19 into the phase II portion which will involve about 112 patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |